Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma

Adamantinomatous craniopharyngioma (ACP) makes up between 6 and 8% of pediatric brain tumors and is the most common pediatric tumor arising in the sellar/suprasellar region of the brain. The 10-year survival for patients diagnosed with craniopharyngioma ranges between 64 and 92%, but complicating fa...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sydney Grob, David M. Mirsky, Andrew M. Donson, Nathan Dahl, Nicholas K. Foreman, Lindsey M. Hoffman, Todd C. Hankinson, Jean M. Mulcahy Levy
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2019-08-01
Edice:Frontiers in Oncology
Témata:
craniopharyngioma
IL-6
tocilizumab
pediatric
bevacizumab
On-line přístup:https://www.frontiersin.org/article/10.3389/fonc.2019.00791/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky